- Home
- ADAP vs CATO Comparison
ADAP vs CATO Comparison
Compare ADAP & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- CATO
- Stock Information
- Founded
- ADAP 2008
- CATO 1946
- Country
- ADAP United Kingdom
- CATO United States
- Employees
- ADAP N/A
- CATO N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- CATO Clothing/Shoe/Accessory Stores
- Sector
- ADAP Health Care
- CATO Consumer Discretionary
- Exchange
- ADAP Nasdaq
- CATO Nasdaq
- Market Cap
- ADAP 71.6M
- CATO 63.9M
- IPO Year
- ADAP 2015
- CATO N/A
- Fundamental
- Price
- ADAP $0.24
- CATO $2.45
- Analyst Decision
- ADAP Strong Buy
- CATO
- Analyst Count
- ADAP 5
- CATO 0
- Target Price
- ADAP $1.83
- CATO N/A
- AVG Volume (30 Days)
- ADAP 2.6M
- CATO 80.4K
- Earning Date
- ADAP 05-14-2025
- CATO 05-22-2025
- Dividend Yield
- ADAP N/A
- CATO 13.96%
- EPS Growth
- ADAP N/A
- CATO N/A
- EPS
- ADAP N/A
- CATO N/A
- Revenue
- ADAP $178,032,000.00
- CATO $649,806,000.00
- Revenue This Year
- ADAP N/A
- CATO N/A
- Revenue Next Year
- ADAP $65.49
- CATO N/A
- P/E Ratio
- ADAP N/A
- CATO N/A
- Revenue Growth
- ADAP 195.34
- CATO N/A
- 52 Week Low
- ADAP $0.20
- CATO $2.19
- 52 Week High
- ADAP $1.48
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- ADAP 37.78
- CATO 38.68
- Support Level
- ADAP $0.23
- CATO $2.19
- Resistance Level
- ADAP $0.26
- CATO $2.97
- Average True Range (ATR)
- ADAP 0.04
- CATO 0.27
- MACD
- ADAP 0.01
- CATO -0.07
- Stochastic Oscillator
- ADAP 31.85
- CATO 16.35
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories primarily in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.